The synthetic neuroactive steroid SGE-516 reduces seizure burden and improves survival in a Dravet syndrome mouse model

Keyphrases

• Acute Symptomatic Seizures 20%
• Anticonvulsant 40%
• Benzodiazepines 60%
• Clobazam 20%
• Conventional Therapy 20%
• Dravet Syndrome 100%
• Epilepsy Phenotype 20%
• Epileptic Encephalopathy 20%
• Extrasynaptic GABAA Receptors 20%
• First-line Therapy 20%
• GABAA Receptor (GABAAR) 20%
• Hyperthermia 20%
• Hyperthermia-induced Seizure 40%
• Mouse Model 100%
• Neuroactive Steroids 100%
• Positive Allosteric Modulator 20%
• Premature Death 20%
• Prolonged Survival 20%
• Refractory Epilepsy 20%
• Rodents 20%
• SCN1A 60%
• Seizure 20%
• Seizure Burden 100%
• Seizure Control 20%
• Seizure Frequency 40%
• Seizure Type 20%
• Spontaneous Seizures 60%
• Stiripentol 20%
• Synaptic 20%
• Synaptic Receptors 20%
• Treatment Effect 20%
• Valproate 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticonvulsant Activity 20%
• Anticonvulsive Agent 20%
• Brain Disease 20%
• Clobazam 20%
• Hyperthermia 60%
• Mouse Model 100%
• Positive Allosteric Modulator 20%
• Prematurity 20%
• Receptor 40%
• Severe Myoclonic Epilepsy in Infancy 100%
• Sodium Valproate 20%
• Stiripentol 20%
• Synapse Receptor 20%

Neuroscience

• Anticonvulsant 40%
• Brain Disease 20%
• Clobazam 20%
• Dravet Syndrome 100%
• GABAA Receptor 40%
• Intractable Epilepsy 20%
• Neuroactive Steroid 100%
• Positive Allosteric Modulator 20%
• Seizure Types 20%
• Stiripentol 20%
• Synapse Receptor 20%